Hematology

A new study concludes that more education is needed for adults 60 and older who must make treatment decisions about their acute myeloid leukemia (AML) diagnosis.

The FDA has approved axicabtagene ciloleucel (axi-cel; Yescarta) as a treatment for adults with relapsed or refractory non-Hodgkin lymphoma (NHL). This CAR T-cell therapy breaks new ground in treatment for the disease.

Survivors of non-Hodgkin lymphoma (NHL) are at a greater risk of heart failure than the general population, according to a recent study published in the Journal of Clinical Oncology.

Copanlisib (BAY 80-6946), a novel PI3K inhibitor, is being combined with standard rituximab (Rituxan)-based regimens in patients with relapsed, indolent non-Hodgkin lymphoma (NHL) in 2 phase III clinical trials that investigators hope will expand treatment options in refractory disease settings, particularly with less toxic alternatives.

The FDA has granted an accelerated approval to copanlisib (Aliqopa) as a treatment for patients with relapsed follicular lymphoma who have received at least 2 least prior systemic therapies.

The FDA has approved gemtuzumab ozogamicin (Mylotarg) for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia (AML).

Tisagenlecleucel (Kymriah), Novartis' newly approved CAR T-cell therapy, will be put on the market with a price of $475,000 for a single infusion, an amount that is within the range anticipated by oncologists and that Novartis characterized as well below a price level that could be justified on cost.

Artist Ryan Berardi’s work goes way beyond pretty pictures. In fact, his 3D animations of what can go wrong during chemotherapy paint a horrific scene.

The FDA has approved CPX-351 (Vyxeos), a fixed-combination of daunorubicin and cytarabine, for adult patients with either newly-diagnosed therapy-related acute myeloid leukemia (t-AML) ot AML with myelodysplasia-related changes (AML-MRC).

CD19 CAR T-cell therapy induced a high-response rate in patients with high-risk, ibrutinib-refractory chronic lymphocytic leukemia (CLL).

Karley Trautman, DNP, ANP-BC, explains her efforts to improve the rates of venous thromboembolism (VTE), as well as the rates of recurrence of VTE in the Blood Cancer and Bone Marrow Transplant program of University of Colorado Hospital.

Expert Jeffrey Lancet, MD, discusses the emerging agents in treating acute myeloid leukemia (AML) and challenges that still exist for improving patient outcome.

The FDA accepted supplemental biologics license application (sBLA) for the use of denosumab (Xgeva) for the prevention of skeletal-related events (SREs) in patients with multiple myeloma.

Karley Trautman, DNP, ANP-BC, of University of Colorado Hospital explains how a quality improvement program helped them to reduce venous thromboembolism (VTE).

The FDA has approved ClearLLab multicolor reagents for the detection of chronic leukemia, acute leukemia, non-Hodgkin lymphoma, multiple myeloma, myelodysplastic syndrome and myeloproliferative neoplasms.

A trial testing the combination of ublituximab, ibrutinib, and umbralisib showed that the combination was well tolerated and had activity across patients with high-risk B-cell malignancies.

There are specific challenges when treating AYA patients with Hodgkin lymphoma.

The FDA has approved subcutaneous rituxumab (Rituxan Hycela) for the treatment of adults with previously untreated

Daratumumab (Darzalex) has been approved for use in combination with pomalidomide (pomalyst) and dexamethasone for patients with multiple myeloma.

Second primary cancers that occur in pediatric, adolescent and young adult (AYA) patients are deadlier than those that occur in older patients.

The UK Myeloma Forum and the British Society for Haematology collaborated to create a comprehensive, multidisciplinary guideline document for the screening, management, and long-term care of patients with myeloma.

The adverse events report featuring FDA labeling changes for bendamustine hydrochloride, nilotinib, dinutuximab.

Subcutaneous co-formulation of rituximab for treatment of patients with certain types of lymphoma and leukemia advances toward approval.